A320 Intraprocedural liquid biopsy during mechanical thrombectomy: cell-free DNA and extracellular vesicle microRNA signatures for risk stratification
Year: 2026
Type: conference-abstract
Abstract: Background/Introduction Mechanical thrombectomy (MT) for large-vessel occlusion achieves high recanalization rates, yet functional outcomes remain variable, and hemorrhagic transformation (HT) causes substantial post-reperfusion morbidity. Established arterial access during MT presents an underexploited opportunity to acquire real-time circulating biomarkers such as cell-free DNA (cfDNA) and extracellular vesicle-packaged microRNAs (EV-miRNAs), without additional procedural risk or delay. Objective/Purpose To synthesize liquid biopsy evidence in acute ischemic stroke and propose a structured intraprocedural blood sampling framework during MT to predict HT and functional recovery. Methods/Case Description A structured review of circulating cfDNA, reperfusion-dependent miRNA clusters, and EV-miRNA profiles in stroke and ischemia–reperfusion models was conducted to evaluate clinical utility, mechanistics, and point-of-care feasibility in the neurointerventional suite. Results/Findings Elevated cfDNA correlates with admission National Institutes of Health Stroke Scale severity and 3-month modified Rankin Scale outcomes; therapeutic benefit concentrates in patients with cfDNA below 10,000 kilogenome-equivalents/L. Reperfusion induces a discrete circulating miRNA signature (miR-1264/1298/448) that peaks within 3 hours post-recanalization. Furthermore, pre-treatment EV-miRNA signatures (including miR-1-3p, miR-133a/b, and miR-383-5p downregulation) strongly correlate with blood–brain barrier breakdown, NOX4-mediated oxidative stress, and subsequent HT risk. EV packaging preserves analyte stability, enabling point-of-care processing. Discussion/Conclusions/Learning Points MT provides a unique environment for real-time biomarker sampling. We propose a three-timepoint sampling framework: femoral sheath baseline at access; guide catheter aspirate during recanalization; and a 3-hour post-MT venous draw. This approach captures paired pre- and post-recanalization profiles without added procedural risk. Prospective, standardized biobanking within ESMINT-affiliated registries is needed to validate cfDNA and EV-miRNA thresholds for predicting HT and guiding post-procedural secondary prevention.
Author: Ryan Beerling Dolovac
Institution: Sir Charles Gairdner Hospital
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7204999859
